Link Cell Therapies shared a post on LinkedIn:
“Link Cell Therapies is excited to announce our emergence from stealth with a $60M Series A bringing total funding to $92M.
Our logic-gated approach – requiring co-expression of two antigens for CAR-T activation – addresses one of the fundamental challenges in solid tumor cell therapy: the lack of truly cancer-specific targets and the on-target, off-tumor toxicity that has limited so many programs.
With our lead program (LNK001) in renal cell carcinoma advancing toward Phase I in 2026 and a colorectal cancer program close behind, we are on track to bring transformative treatments to patients in need.
We are grateful to our investors who are committed to our mission, including Samsara Biocapital, Sheatree Capital, JJDC Inc, Bristol Myers Squibb, Kyowa Kirin, Wing Venture Capital, and Sherpa Healthcare Partners.”
Robbie Majzner, Associate Professor at Dana-Farber Cancer Institute, shared this post, adding:
“Really excited for the news today as Link Cell Therapies, a company I co-founded with Crystal Mackall, officially launches out of stealth with the announcement of their Series A. The company has been hard at work for several years turning a prototype Boolean-logic AND-gated CAR T cell that was the brainchild of Aidan Tousley into a real product with real potential to help patients.
With LNK001 headed towards a Phase 1 trial in renal cell carcinoma in 2026, we are excited about the team Link has built – and we hope their work will redefine the universe of antigens and cancers we can target with CAR T cells. Very fortunate to have received backing from Samsara, Sheatree, JJDC, Wing VC, BMS, Kyowa Kirin, Sherpa and others!”
More posts featuring Link Cell Therapies on OncoDaily.